Skip to main content

Table 2 Immunohistochemical positivity of PRMT1, ZEB1, RUNX1 and TWIST1 among different tumor types

From: PRMT1 expression in renal cell tumors- application in differential diagnosis and prognostic relevance

Histological subtype

PRMT1

ZEB1

RUNX1

TWIST1

+

+

+

+

ccRCC

73/120 (60.8)

47/120 (39.2)

37/113 (32.7)

76/113 (67.3)

70/117 (59.8)

47/117 (40.2)

112/115 (97.4)

3/115 (2.6)

pRCC I

4/7 (57.1)

3/7 (42.9)

0/7 (0)

7/7 (100)

2/7 (28.6)

5/7 (71.4)

7/7 (100)

0/7 (0.0)

pRCC II

12/16 (75.0)

4/16 (25.0)

1/16 (6.6)

14/15 (93.4)

7/16 (43.8)

9/16 (56.3)

16/16 (100)

0/16 (0.0)

chRCC

12/28 (42.8)

16/28 (57.2)

2/27 (7.1)

25/27 (92.9)

13/28 (46.4)

15/28 (53.6)

28/28 (100)

0/28 (0.0)

RO

24/25 (96.1)

1/25 (9.4)

24/25 (96.0)

1/25 (4.0)

9/25 (36.0)

16/25 (64.0)

25/25 (100)

0/25 (0.0)

CDC

5/7 (71.4)

2/7 (28.6)

3/7 (42.9)

4/7 (57.1)

3/7 (42.9)

4/7 (57.1)

7/7 (100)

0/7 (0.0)

MLCRN-LMP

5/5 (100)

0/0 (0.0)

0/5 (0)

5/5 (100)

5/5 (100)

0/5 (0.0)

5/5 (100)

0/5 (0.0)

P value

0.044*

<0.001*

0.149

0.897

  1. Abbreviations: PRMT1, protein arginine methyltransferase 1; ZEB1, Zinc Finger E-Box Binding Homeobox 1; RUNX1, Runt-related transcription factor 1; TWIST1, Twist Family BHLH Transcription Factor 1; ccRCC, clear cell renal cell carcinomas; pRCC I, papillary renal cell carcinoma type I; pRCC II, papillary renal cell carcinoma type I; chRCC, chromophobe renal cell carcinoma;CDC, collecting duct carcinomas-Bellini; MLCRN-LMP, multilocular cystic renal neoplasm of low malignant potential; +, positive; −, negative
  2. *Statistically significant p-value